Dance Biopharm and Phillips-Medisize Unite to Develop Advanced Inhaled Insulin Delivery

Dance Biopharm Holdings Inc., a privately-held biotechnology company focused on the development of Dance 501, a proprietary ‘soft-mist’ inhaled insulin product to treat diabetes, is pleased to announce that Dance has entered into a joint development agreement (JDA) with Phillips-Medisize, LLC, a subsidiary of Molex Electronic Technologies, LLC, a developer of electronic solutions, to develop a version of the Dance 501 device that has data connectivity for better management of diabetes treatment.
 
Phillips-Medisize brings world class software and hardware capabilities to implement Dance’s designs. Phillips-Medisize is currently involved in the design and manufacture of clinical devices for Dance and, based on this JDA, Dance has awarded Phillips-Medisize the development work associated with future enhancements to Dance’s devices as well as the commercial manufacturing of Dance’s inhaled insulin device when it comes to market.
 
“We believe our inhaled insulin product is state of the art and well-differentiated from powder based, non-electronic technology. It provides a platform for applying advanced digital medicine for diabetes management. We love Phillips-Medisize and the solutions they offer for this aspect of our product,” stated John Patton, chairman and chief executive officer of Dance Biopharm. “Inhaled insulin offers the possibility of a cost effective, significant improvement in lifestyle—ease-of-use and compliance—for diabetic patients all over the world. We believe that our convenient soft-mist product candidate may someday improve the lives of millions of patients.”
 
“Advancements in drug delivery device technology have created new ways to administer drugs, thereby improving reliability and therapy adherence. Dance’s breathable insulin technology will be a game changer for patients living with diabetes,” said Bill Welch, chief technology officer, Phillips-Medisize. “Working closely with Dance to support a connected health strategy, product development, and manufacturing can enable faster global access to Dance’s innovative insulin delivery solution.”
 
“Pulmonary drug delivery devices are one of the fastest growing segments in the drug delivery market,” said Matt Jennings, chief executive officer, Phillips-Medisize. “We are excited to support Dance in bringing a Connected Health Pulmonary drug delivery system to the marketplace. We are also looking forward to collaborating on the design, development, manufacturing, and eventual back office support and user analytics for a connected health solution that may improve drug delivery efficiency, overall patient experience and improved outcomes.”